Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Oncternal Therapeutics stock | $3.68

Learn how to easily invest in Oncternal Therapeutics stock.

Oncternal Therapeutics Inc is a biotechnology business based in the US. Oncternal Therapeutics shares (ONCT) are listed on the NASDAQ and all prices are listed in US Dollars. Oncternal Therapeutics employs 12 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Oncternal Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ONCT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Oncternal Therapeutics stock price (NASDAQ: ONCT)

Use our graph to track the performance of ONCT stocks over time.

Oncternal Therapeutics shares at a glance

Information last updated 2021-10-24.
Latest market close$3.68
52-week range$1.49 - $10.56
50-day moving average $4.10
200-day moving average $4.83
Wall St. target price$15.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.56

Buy Oncternal Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Oncternal Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Oncternal Therapeutics price performance over time

Historical closes compared with the close of $3.68 from 2021-10-22

1 week (2021-10-18) -2.90%
1 month (2021-09-24) -16.36%
3 months (2021-07-23) -6.84%
6 months (2021-04-23) -42.05%
1 year (2020-10-23) 120.36%
2 years (2019-10-24) -33.27%
3 years (2018-10-24) 131.45%
5 years (2016-10-24) 327.91%

Oncternal Therapeutics financials

Revenue TTM $3.8 million
Gross profit TTM $-9,169,000
Return on assets TTM -20.52%
Return on equity TTM -36.72%
Profit margin 0%
Book value $2.08
Market capitalisation $181.7 million

TTM: trailing 12 months

Shorting Oncternal Therapeutics shares

There are currently 1.7 million Oncternal Therapeutics shares held short by investors – that's known as Oncternal Therapeutics's "short interest". This figure is 11.2% down from 1.9 million last month.

There are a few different ways that this level of interest in shorting Oncternal Therapeutics shares can be evaluated.

Oncternal Therapeutics's "short interest ratio" (SIR)

Oncternal Therapeutics's "short interest ratio" (SIR) is the quantity of Oncternal Therapeutics shares currently shorted divided by the average quantity of Oncternal Therapeutics shares traded daily (recently around 505426.70623145). Oncternal Therapeutics's SIR currently stands at 3.37. In other words for every 100,000 Oncternal Therapeutics shares traded daily on the market, roughly 3370 shares are currently held short.

However Oncternal Therapeutics's short interest can also be evaluated against the total number of Oncternal Therapeutics shares, or, against the total number of tradable Oncternal Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Oncternal Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Oncternal Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0353% of the tradable shares (for every 100,000 tradable Oncternal Therapeutics shares, roughly 35 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Oncternal Therapeutics.

Find out more about how you can short Oncternal Therapeutics stock.

Oncternal Therapeutics share dividends

We're not expecting Oncternal Therapeutics to pay a dividend over the next 12 months.

Have Oncternal Therapeutics's shares ever split?

Oncternal Therapeutics's shares were split on a 1:7 basis on 9 June 2019. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Oncternal Therapeutics shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Oncternal Therapeutics shares which in turn could have impacted Oncternal Therapeutics's share price.

Oncternal Therapeutics share price volatility

Over the last 12 months, Oncternal Therapeutics's shares have ranged in value from as little as $1.49 up to $10.56. A popular way to gauge a stock's volatility is its "beta".

ONCT.US volatility(beta: 1.55)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oncternal Therapeutics's is 1.5459. This would suggest that Oncternal Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Oncternal Therapeutics overview

Oncternal Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.

Frequently asked questions

What percentage of Oncternal Therapeutics is owned by insiders or institutions?
Currently 11.818% of Oncternal Therapeutics shares are held by insiders and 31.475% by institutions.
How many people work for Oncternal Therapeutics?
Latest data suggests 12 work at Oncternal Therapeutics.
When does the fiscal year end for Oncternal Therapeutics?
Oncternal Therapeutics's fiscal year ends in December.
Where is Oncternal Therapeutics based?
Oncternal Therapeutics's address is: 12230 El Camino Real, San Diego, CA, United States, 92130
What is Oncternal Therapeutics's ISIN number?
Oncternal Therapeutics's international securities identification number is: US68236P1075
What is Oncternal Therapeutics's CUSIP number?
Oncternal Therapeutics's Committee on Uniform Securities Identification Procedures number is: 40052B108

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site